Cargando…

[(124)I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease

Several fluorine-18-labeled PET β-amyloid (Aβ) plaque radiotracers for Alzheimer’s disease (AD) are in clinical use. However, no radioiodinated imaging agent for Aβ plaques has been successfully moved forward for either single-photon emission computed tomography (SPECT) or positron emission tomograp...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Grace A.H., Liang, Christopher, Mukherjee, Jogeshwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319930/
https://www.ncbi.nlm.nih.gov/pubmed/35889425
http://dx.doi.org/10.3390/molecules27144552
_version_ 1784755669971238912
author Nguyen, Grace A.H.
Liang, Christopher
Mukherjee, Jogeshwar
author_facet Nguyen, Grace A.H.
Liang, Christopher
Mukherjee, Jogeshwar
author_sort Nguyen, Grace A.H.
collection PubMed
description Several fluorine-18-labeled PET β-amyloid (Aβ) plaque radiotracers for Alzheimer’s disease (AD) are in clinical use. However, no radioiodinated imaging agent for Aβ plaques has been successfully moved forward for either single-photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging. Radioiodinated pyridyl benzofuran derivatives for the SPECT imaging of Aβ plaques using iodine-123 and iodine-125 are being pursued. In this study, we assess the iodine-124 radioiodinated pyridyl benzofuran derivative 5-(5-[(124)I]iodobenzofuran-2-yl)-N,N-dimethylpyridin-2-amine ([(124)I]IBETA) (Ki = 2.36 nM) for utilization in PET imaging for Aβ plaques. We report our findings on the radioiododestannylation reaction used to prepare [(124/125)I]IBETA and evaluate its binding to Aβ plaques in a 5 × FAD mouse model and postmortem human AD brain. Both [(125)I]IBETA and [(124)I]IBETA are produced in >25% radiochemical yield and >85% radiochemical purity. The in vitro binding of [(125)I]IBETA and [(124)I]IBETA in transgenic 5 × FAD mouse model for Aβ plaques was high in the frontal cortex, anterior cingulate, thalamus, and hippocampus, which are regions of high Aβ accumulation, with very little binding in the cerebellum (ratio of brain regions to cerebellum was >5). The in vitro binding of [(125)I]IBETA and [(124)I]IBETA in postmortem human AD brains was higher in gray matter containing Aβ plaques compared to white matter (ratio of gray to white matter was >5). Anti-Aβ immunostaining strongly correlated with [(124)/(125)I]IBETA regional binding in both the 5 × FAD mouse and postmortem AD human brains. The binding of [(124)/(125)I]IBETA in 5 × FAD mouse and postmortem human AD brains was displaced by the known Aβ plaque imaging agent, Flotaza. Preliminary PET/CT studies of [(124)I]IBETA in the 5 × FAD mouse model suggested [(124)I]IBETA was relatively stable in vivo with a greater localization of [(124)I]IBETA in the brain regions with a high concentration of Aβ plaques. Some deiodination was observed at later time points. Therefore, [(124)I]IBETA may potentially be a useful PET radioligand for Aβ plaques in brain studies.
format Online
Article
Text
id pubmed-9319930
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93199302022-07-27 [(124)I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease Nguyen, Grace A.H. Liang, Christopher Mukherjee, Jogeshwar Molecules Article Several fluorine-18-labeled PET β-amyloid (Aβ) plaque radiotracers for Alzheimer’s disease (AD) are in clinical use. However, no radioiodinated imaging agent for Aβ plaques has been successfully moved forward for either single-photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging. Radioiodinated pyridyl benzofuran derivatives for the SPECT imaging of Aβ plaques using iodine-123 and iodine-125 are being pursued. In this study, we assess the iodine-124 radioiodinated pyridyl benzofuran derivative 5-(5-[(124)I]iodobenzofuran-2-yl)-N,N-dimethylpyridin-2-amine ([(124)I]IBETA) (Ki = 2.36 nM) for utilization in PET imaging for Aβ plaques. We report our findings on the radioiododestannylation reaction used to prepare [(124/125)I]IBETA and evaluate its binding to Aβ plaques in a 5 × FAD mouse model and postmortem human AD brain. Both [(125)I]IBETA and [(124)I]IBETA are produced in >25% radiochemical yield and >85% radiochemical purity. The in vitro binding of [(125)I]IBETA and [(124)I]IBETA in transgenic 5 × FAD mouse model for Aβ plaques was high in the frontal cortex, anterior cingulate, thalamus, and hippocampus, which are regions of high Aβ accumulation, with very little binding in the cerebellum (ratio of brain regions to cerebellum was >5). The in vitro binding of [(125)I]IBETA and [(124)I]IBETA in postmortem human AD brains was higher in gray matter containing Aβ plaques compared to white matter (ratio of gray to white matter was >5). Anti-Aβ immunostaining strongly correlated with [(124)/(125)I]IBETA regional binding in both the 5 × FAD mouse and postmortem AD human brains. The binding of [(124)/(125)I]IBETA in 5 × FAD mouse and postmortem human AD brains was displaced by the known Aβ plaque imaging agent, Flotaza. Preliminary PET/CT studies of [(124)I]IBETA in the 5 × FAD mouse model suggested [(124)I]IBETA was relatively stable in vivo with a greater localization of [(124)I]IBETA in the brain regions with a high concentration of Aβ plaques. Some deiodination was observed at later time points. Therefore, [(124)I]IBETA may potentially be a useful PET radioligand for Aβ plaques in brain studies. MDPI 2022-07-17 /pmc/articles/PMC9319930/ /pubmed/35889425 http://dx.doi.org/10.3390/molecules27144552 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nguyen, Grace A.H.
Liang, Christopher
Mukherjee, Jogeshwar
[(124)I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease
title [(124)I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease
title_full [(124)I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease
title_fullStr [(124)I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease
title_full_unstemmed [(124)I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease
title_short [(124)I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease
title_sort [(124)i]ibeta: a new aβ plaque positron emission tomography imaging agent for alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319930/
https://www.ncbi.nlm.nih.gov/pubmed/35889425
http://dx.doi.org/10.3390/molecules27144552
work_keys_str_mv AT nguyengraceah 124iibetaanewabplaquepositronemissiontomographyimagingagentforalzheimersdisease
AT liangchristopher 124iibetaanewabplaquepositronemissiontomographyimagingagentforalzheimersdisease
AT mukherjeejogeshwar 124iibetaanewabplaquepositronemissiontomographyimagingagentforalzheimersdisease